Cellerix, S.A. – Product Pipeline Review – Q4 2010

Date: December 1, 2010
Pages: 38
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: CE60A7FA724EN
Leaflet:

Download PDF Leaflet

Cellerix, S.A. – Product Pipeline Review – Q4 2010
Cellerix, S.A. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Cellerix, S.A. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Cellerix, S.A. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Cellerix, S.A. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Cellerix, S.A. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Cellerix, S.A.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Cellerix, S.A.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Cellerix, S.A. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Cellerix, S.A.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Cellerix, S.A..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Cellerix, S.A. and identify potential opportunities in those areas.
Cellerix, S.A. Snapshot
Cellerix, S.A. Overview
Key Facts
Cellerix, S.A. – Research and Development Overview
Key Therapeutic Areas
Cellerix, S.A. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Cellerix, S.A. – Pipeline Products Glance
Cellerix, S.A. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cellerix, S.A. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cellerix, S.A.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cellerix, S.A. – Drug Profiles
Ontaril
  Product Description
  Mechanism of Action
  R&D Progress
Cx501
  Product Description
  Mechanism of Action
  R&D Progress
Cx601
  Product Description
  Mechanism of Action
  R&D Progress
Cx601
  Product Description
  Mechanism of Action
  R&D Progress
Cx602
  Product Description
  Mechanism of Action
  R&D Progress
Cx611
  Product Description
  Mechanism of Action
  R&D Progress
Cx621
  Product Description
  Mechanism of Action
  R&D Progress
Cx911
  Product Description
  Mechanism of Action
  R&D Progress
Cellerix, S.A. – Pipeline Analysis
Cellerix, S.A. – Pipeline Products by Therapeutic Class
Cellerix, S.A. Pipeline Products By Target
Cellerix, S.A. – Pipeline Products by Route of Administration
Cellerix, S.A. – Pipeline Products by Molecule Type
Cellerix, S.A. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 21, 2009: Gamida Cell and Cellerix Partner on Feasibility Study
Sep 07, 2009: Cellerixs Cx601 Designated Orphan Medicinal Product By The EMEA
Oct 21, 2008: Cellerix's Ontaril closer to the market
Apr 15, 2008: Cellerix Registers The Name Ontaril For Its Medicine Cx401
Financial Deals Landscape
Cellerix, S.A., Deals Summary, 2004 to 2010
Cellerix, S.A. Detailed Deal Summary
Venture Financing
Cellerix Secures $40 Million In Series C Round Of Venture Financing
Licensing Agreements
Axcan Pharma Enters Into Licenisng Agreement With Cellerix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Cellerix, S.A. – Pipeline by Therapy Area and Indication, 2010
Cellerix, S.A. – Pipeline by Stage of Development, 2010
Cellerix, S.A. – Monotherapy Products in Pipeline, 2010
Cellerix, S.A. – Phase III, 2010
Cellerix, S.A. - Phase II, 2010
Cellerix, S.A. - Phase I, 2010
Cellerix, S.A. - Pipeline By Therapeutic Class, 2010
Cellerix, S.A. - Pipeline By Target, 2010
Cellerix, S.A. – Pipeline By Route of Administration, 2010
Cellerix, S.A. – Pipeline By Molecule Type, 2010
Cellerix, S.A., Subsidiaries
Cellerix, S.A., Deals Summary, 2004 to 2010 31

LIST OF FIGURES

Cellerix, S.A. – Pipeline by Therapy Area and Indication, 2010
Cellerix, S.A. – Pipeline by Stage of Development, 2010
Cellerix, S.A. – Monotherapy Products in Pipeline, 2010
Cellerix, S.A. – Pipeline By Therapeutic Class, 2010
Cellerix, S.A. - Pipeline By Target, 2010
Cellerix, S.A. – Pipeline By Route of Administration, 2010
Cellerix, S.A. – Pipeline By Molecule Type, 2010 26
Bronchiolitis - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 25 pages
Rhinosinusitis - Pipeline Review, Q2 2011 US$ 500.00 Apr, 2011 · 34 pages
Pulmonary Embolism – Pipeline Review, H2 2012 US$ 2,000.00 Oct, 2012 · 60 pages
Spasticity - Pipeline Review, H2 2014 US$ 2,000.00 Oct, 2014 · 74 pages

Ask Your Question

Cellerix, S.A. – Product Pipeline Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: